What is Adela?
Adela Bio is a specialized biotechnology firm dedicated to the development of advanced blood-based cancer detection and monitoring solutions. At the core of its technological stack is a sophisticated DNA methylation-based liquid biopsy platform. This innovation allows for the early identification of oncological markers, providing clinicians with actionable data to assess treatment efficacy and track disease progression with unprecedented precision. By moving away from traditional, invasive biopsy methods, Adela is effectively lowering the barrier to routine cancer screening and longitudinal patient monitoring. The company's market position is bolstered by its ability to integrate complex genomic data into clinical workflows, thereby addressing a critical gap in the current standard of care for oncology patients.
How much funding has Adela raised?
Adela has raised a total of $53M across 2 funding rounds:
Other Financing Round
$48M
Debt
$5M
Other Financing Round (2023): $48M with participation from F-Prime Capital Partners, RA Capital Management, OrbiMed, Decheng Capital, and Deerfield
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Adela
F-Prime Capital Partners
A venture capital firm with a deep history in healthcare and technology, providing a multidisciplinary team of scientists and clinicians to support early-stage innovation.
RA Capital Management
A multi-stage investment manager that utilizes its internal TechAtlas think tank to conduct evidence-based analysis of life science and diagnostic companies.
OrbiMed
A specialized healthcare investment firm with extensive expertise in biopharmaceuticals and diagnostics, known for its hands-on approach to operational optimization and strategic market positioning.
What's next for Adela?
With the recent influx of capital, Adela is well-positioned to scale its operational capabilities and expand its clinical trial footprint. The strategic focus will likely shift toward securing regulatory approvals and establishing commercial partnerships that can integrate its liquid biopsy technology into broader healthcare systems. As the company matures, the emphasis will remain on refining its diagnostic algorithms to improve sensitivity and specificity across a wider range of cancer types. Furthermore, the firm is expected to leverage its strong investor backing to navigate the complexities of the global diagnostics market, potentially exploring new therapeutic areas where DNA methylation analysis can provide a competitive advantage in patient outcomes and disease management.
See full Adela company page
